321 related articles for article (PubMed ID: 36466882)
1. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
[TBL] [Abstract][Full Text] [Related]
2. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
Li L; Wang M; Hao J; Han J; Fu T; Bai J; Tian M; Jin N; Zhu G; Li C
Int J Biol Macromol; 2021 Nov; 190():409-416. PubMed ID: 34499954
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
Front Immunol; 2022; 13():858904. PubMed ID: 35592324
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
[TBL] [Abstract][Full Text] [Related]
5. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
Ma C; Li Y; Wang L; Zhao G; Tao X; Tseng CT; Zhou Y; Du L; Jiang S
Vaccine; 2014 Apr; 32(18):2100-8. PubMed ID: 24560617
[TBL] [Abstract][Full Text] [Related]
6. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern.
Yang J; Liu MQ; Liu L; Li X; Xu M; Lin H; Liu S; Hu Y; Li B; Liu B; Li M; Sun Y; Chen YQ; Shi ZL; Yan H
Cell Mol Immunol; 2022 Nov; 19(11):1279-1289. PubMed ID: 36220993
[TBL] [Abstract][Full Text] [Related]
7. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
[TBL] [Abstract][Full Text] [Related]
8. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z
EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.
Lei H; Alu A; Yang J; Ren W; He C; Lan T; He X; Yang L; Li J; Wang Z; Song X; Wang W; Lu G; Wei X
Signal Transduct Target Ther; 2022 May; 7(1):159. PubMed ID: 35581200
[TBL] [Abstract][Full Text] [Related]
10. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs.
Mosqueda J; Hernández-Silva DJ; Vega-López MA; Vega-Rojas LJ; Beltrán R; Velasco-Elizondo A; Ramírez-Estudillo MDC; Fragoso-Saavedra M; Pérez-Almeida C; Hernández J; Melgoza-González EA; Hinojosa-Trujillo D; Mercado-Uriostegui MÁ; Mejía-López AS; Rivera-Ballesteros C; García-Gasca T
Front Immunol; 2023; 14():1276950. PubMed ID: 38179057
[TBL] [Abstract][Full Text] [Related]
12. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
Zhang T; Wang Z; Yang J; Xu X
J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
[TBL] [Abstract][Full Text] [Related]
14. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
15. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
17. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
Rothen DA; Krenger PS; Nonic A; Balke I; Vogt AS; Chang X; Manenti A; Vedovi F; Resevica G; Walton SM; Zeltins A; Montomoli E; Vogel M; Bachmann MF; Mohsen MO
Allergy; 2022 Aug; 77(8):2446-2458. PubMed ID: 35403221
[TBL] [Abstract][Full Text] [Related]
19. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
20. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
